Home » Clinical Trials » Medical Areas
Therapeutic Areas: Gastroenterology
Disease Category: Irritable Bowel Syndrome (IBS)
Trial Information
A Randomized, Double-blind, Placebo-controlled Study of AGI-003 (Arverapamil) in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
A 14 week, double-blind study using Verapamil R for treatment of Irritable Bowel Syndrome with Diarrhea. All subjects will need to complete dialy diary entries by phone in conjunction with office visits to the site.
Patient Inclusion Criteria:
- 18 - 70 years old
- DIARRHEA predominant with symptoms for at least the past 3 months
Patient Exclusion Criteria:
- Cardiovascular disease where treatment with Verapamil is contraindicated
- Celiac disease, acute diverticulitis or duodenal ulcers
- Barrett’s or grade 3 esophagitis
- Crohn’s disease, ulcerative colitis or severe GERD
Cheryl Nickles, Recruitment Coordinator
Chase Medical Research, LLC
500 Chase Parkway, 3rd Floor
Waterbury CT 06708
Phone: (203) 419-4420
Fax: (203) 465-7924
EMail: medical_research@chasemr.com
View Google Map
Research Center Information: Chase Medical Research, LLC
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
